Erasca (ERAS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 26, 2026, to be held virtually for shareholders of record as of April 27, 2026.
Proxy materials, including the notice, proxy statement, and annual report or Form 10-K, are available online, with paper copies available upon request.
Voting matters and shareholder proposals
Shareholders will vote to elect three Class II directors for a three-year term expiring at the 2029 annual meeting.
Ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is on the agenda.
Additional business may be transacted as appropriate during the meeting.
Board of directors and corporate governance
Nominees for Class II director positions are Alexander W. Casdin, Julie Hambleton, M.D., and Michael D. Varney, Ph.D.
The board recommends a vote in favor of all director nominees and the auditor ratification.
Latest events from Erasca
- Early clinical milestones, extended cash runway, and strong preclinical data drive optimism.ERAS
BofA Securities 2025 Healthcare Conference9 Jul 2026 - Promising RAS/MAPK-targeted therapies advance with strong data and key milestones ahead.ERAS
43rd Annual J.P. Morgan Healthcare Conference 20258 Jul 2026 - Naporafenib plus trametinib shows strong efficacy in NRAS-mutant melanoma; RAS franchise advances to IND in 2025.ERAS
R&D Update8 Jul 2026 - ERAS-0015 shows high potency and safety at low doses, with broad development and combination plans.ERAS
Guggenheim Securities Emerging Outlook: Biotech Summit 20268 Jul 2026 - Lead RAS-targeting agents show high NSCLC response rates and favorable safety, with key updates ahead.ERAS
Jefferies Global Healthcare Conference 20263 Jun 2026 - Promising efficacy and safety for pan-RAS inhibitor, with pivotal trials and combos advancing.ERAS
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 net loss hit $183.4M on license expense; cash runway extends into H2 2028.ERAS
Q1 202611 May 2026 - Leading RAS/MAPK-targeted therapies show strong preclinical and early clinical promise.ERAS
Corporate presentation1 May 2026 - Virtual annual meeting to elect directors, ratify auditor, and highlight governance and ESG practices.ERAS
Proxy filing28 Apr 2026